Assay Development and Screening
Betty Chan, PhD
Director, Biochemistry and Biophysics
Auron Therapeutics, Massachusetts, United States
Differentiation therapy is a unique approach to treating cancer without the challenging side effects associated with current treatments, which depend on killing tumor cells. Auron Therapeutics’ multi-omics translational platform has identified therapeutic targets that could potentially reactivate and/or reprogram cellular pathways in cancer tissues to a more normal phenotype. For some of these targets, potent and selective small molecules with desired drug-like properties have not previously been described. In this presentation, Auron’s application of biochemical and biophysical assays to enable discovery and early characterization of novel chemical matter for a differentiation target will be shown.